Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome

Anita T. Tandle, Maura Calvani, Badarch Uranchimeg, David Zahavi, Giovanni Melillo, Steven K. Libutti

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The majority of human tumors are angiogenesis dependent. Understanding the specific mechanisms that contribute to angiogenesis may offer the best approach to develop therapies to inhibit angiogenesis in cancer. Endothelial monocyte activating polypeptide-II (EMAP-II) is an anti-angiogenic cytokine with potent effects on endothelial cells (ECs). It inhibits EC proliferation and cord formation, and it suppresses primary and metastatic tumor growth in-vivo. However, very little is known about the molecular mechanisms behind the anti-angiogenic activity of EMAP-II. In the present study, we explored the molecular mechanism behind the anti-angiogenic activity exerted by this protein on ECs. Our results demonstrate that EMAP-II binds to the cell surface α5β1 integrin receptor. The cell surface binding of EMAP-II results in its internalization into the cytoplasmic compartment where it interacts with its cytoplasmic partner PSMA7, a component of the proteasome degradation pathway. This interaction increases hypoxia-inducible factor 1-alpha (HIF-1α) degradation under hypoxic conditions. The degradation results in the inhibition of HIF-1α mediated transcriptional activity as well as HIF-1α mediated angiogenic sprouting of ECs. HIF-1α plays a critical role in angiogenesis by activating a variety of angiogenic growth factors. Our results suggest that one of the major anti-angiogenic functions of EMAP-II is exerted through its inhibition of the HIF-1α activities.

Original languageEnglish (US)
Pages (from-to)1850-1859
Number of pages10
JournalExperimental Cell Research
Volume315
Issue number11
DOIs
StatePublished - Jul 1 2009

Fingerprint

Hypoxia-Inducible Factor 1
Proteasome Endopeptidase Complex
Endothelial Cells
Cell Hypoxia
Neoplasms
Angiogenesis Inducing Agents
Integrins
Intercellular Signaling Peptides and Proteins
Cell Proliferation
small inducible cytokine subfamily E, member 1
Hypoxia
Cytokines
Growth
Proteins

Keywords

  • Angiogenesis
  • EMAP-II
  • HIF-1α
  • Integrin receptor
  • Proteasome

ASJC Scopus subject areas

  • Cell Biology

Cite this

Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome. / Tandle, Anita T.; Calvani, Maura; Uranchimeg, Badarch; Zahavi, David; Melillo, Giovanni; Libutti, Steven K.

In: Experimental Cell Research, Vol. 315, No. 11, 01.07.2009, p. 1850-1859.

Research output: Contribution to journalArticle

Tandle, Anita T. ; Calvani, Maura ; Uranchimeg, Badarch ; Zahavi, David ; Melillo, Giovanni ; Libutti, Steven K. / Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome. In: Experimental Cell Research. 2009 ; Vol. 315, No. 11. pp. 1850-1859.
@article{def89f444b5f4a71b863cd9b52d316e4,
title = "Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome",
abstract = "The majority of human tumors are angiogenesis dependent. Understanding the specific mechanisms that contribute to angiogenesis may offer the best approach to develop therapies to inhibit angiogenesis in cancer. Endothelial monocyte activating polypeptide-II (EMAP-II) is an anti-angiogenic cytokine with potent effects on endothelial cells (ECs). It inhibits EC proliferation and cord formation, and it suppresses primary and metastatic tumor growth in-vivo. However, very little is known about the molecular mechanisms behind the anti-angiogenic activity of EMAP-II. In the present study, we explored the molecular mechanism behind the anti-angiogenic activity exerted by this protein on ECs. Our results demonstrate that EMAP-II binds to the cell surface α5β1 integrin receptor. The cell surface binding of EMAP-II results in its internalization into the cytoplasmic compartment where it interacts with its cytoplasmic partner PSMA7, a component of the proteasome degradation pathway. This interaction increases hypoxia-inducible factor 1-alpha (HIF-1α) degradation under hypoxic conditions. The degradation results in the inhibition of HIF-1α mediated transcriptional activity as well as HIF-1α mediated angiogenic sprouting of ECs. HIF-1α plays a critical role in angiogenesis by activating a variety of angiogenic growth factors. Our results suggest that one of the major anti-angiogenic functions of EMAP-II is exerted through its inhibition of the HIF-1α activities.",
keywords = "Angiogenesis, EMAP-II, HIF-1α, Integrin receptor, Proteasome",
author = "Tandle, {Anita T.} and Maura Calvani and Badarch Uranchimeg and David Zahavi and Giovanni Melillo and Libutti, {Steven K.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1016/j.yexcr.2009.03.021",
language = "English (US)",
volume = "315",
pages = "1850--1859",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "11",

}

TY - JOUR

T1 - Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome

AU - Tandle, Anita T.

AU - Calvani, Maura

AU - Uranchimeg, Badarch

AU - Zahavi, David

AU - Melillo, Giovanni

AU - Libutti, Steven K.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - The majority of human tumors are angiogenesis dependent. Understanding the specific mechanisms that contribute to angiogenesis may offer the best approach to develop therapies to inhibit angiogenesis in cancer. Endothelial monocyte activating polypeptide-II (EMAP-II) is an anti-angiogenic cytokine with potent effects on endothelial cells (ECs). It inhibits EC proliferation and cord formation, and it suppresses primary and metastatic tumor growth in-vivo. However, very little is known about the molecular mechanisms behind the anti-angiogenic activity of EMAP-II. In the present study, we explored the molecular mechanism behind the anti-angiogenic activity exerted by this protein on ECs. Our results demonstrate that EMAP-II binds to the cell surface α5β1 integrin receptor. The cell surface binding of EMAP-II results in its internalization into the cytoplasmic compartment where it interacts with its cytoplasmic partner PSMA7, a component of the proteasome degradation pathway. This interaction increases hypoxia-inducible factor 1-alpha (HIF-1α) degradation under hypoxic conditions. The degradation results in the inhibition of HIF-1α mediated transcriptional activity as well as HIF-1α mediated angiogenic sprouting of ECs. HIF-1α plays a critical role in angiogenesis by activating a variety of angiogenic growth factors. Our results suggest that one of the major anti-angiogenic functions of EMAP-II is exerted through its inhibition of the HIF-1α activities.

AB - The majority of human tumors are angiogenesis dependent. Understanding the specific mechanisms that contribute to angiogenesis may offer the best approach to develop therapies to inhibit angiogenesis in cancer. Endothelial monocyte activating polypeptide-II (EMAP-II) is an anti-angiogenic cytokine with potent effects on endothelial cells (ECs). It inhibits EC proliferation and cord formation, and it suppresses primary and metastatic tumor growth in-vivo. However, very little is known about the molecular mechanisms behind the anti-angiogenic activity of EMAP-II. In the present study, we explored the molecular mechanism behind the anti-angiogenic activity exerted by this protein on ECs. Our results demonstrate that EMAP-II binds to the cell surface α5β1 integrin receptor. The cell surface binding of EMAP-II results in its internalization into the cytoplasmic compartment where it interacts with its cytoplasmic partner PSMA7, a component of the proteasome degradation pathway. This interaction increases hypoxia-inducible factor 1-alpha (HIF-1α) degradation under hypoxic conditions. The degradation results in the inhibition of HIF-1α mediated transcriptional activity as well as HIF-1α mediated angiogenic sprouting of ECs. HIF-1α plays a critical role in angiogenesis by activating a variety of angiogenic growth factors. Our results suggest that one of the major anti-angiogenic functions of EMAP-II is exerted through its inhibition of the HIF-1α activities.

KW - Angiogenesis

KW - EMAP-II

KW - HIF-1α

KW - Integrin receptor

KW - Proteasome

UR - http://www.scopus.com/inward/record.url?scp=67349132912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349132912&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2009.03.021

DO - 10.1016/j.yexcr.2009.03.021

M3 - Article

C2 - 19362550

AN - SCOPUS:67349132912

VL - 315

SP - 1850

EP - 1859

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 11

ER -